NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis $3.63 -0.33 (-8.33%) (As of 10:53 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Sutro Biopharma Stock (NASDAQ:STRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sutro Biopharma alerts:Sign Up Key Stats Today's Range$3.60▼$3.9850-Day Range$3.25▼$4.6152-Week Range$2.13▼$6.13Volume173,913 shsAverage Volume800,655 shsMarket Capitalization$297.53 millionP/E RatioN/ADividend YieldN/APrice Target$12.14Consensus RatingBuy Company OverviewSutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More… "January Surprise" Could Cut Bull Run Short, Says Banking Expert (Ad)According to one of America's most trusted banking experts – followed by names at Wells Fargo, UBS, and Barclays – the U.S. economy could look very different by January 20. Click here to see Dan's warning (and possible solution) for America. Sutro Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks90th Percentile Overall ScoreSTRO MarketRank™: Sutro Biopharma scored higher than 90% of companies evaluated by MarketBeat, and ranked 133rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSutro Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Sutro Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($2.96) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.93% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 16.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted2.93% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 16.08%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.93 News SentimentSutro Biopharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for STRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sutro Biopharma's insider trading history. Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Stock News HeadlinesSutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 13 at 4:30 PM | globenewswire.comAnalysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) PT at $12.13November 8, 2024 | americanbankingnews.com"January Surprise" Could Cut Bull Run Short, Says Banking ExpertAccording to one of America's most trusted banking experts – followed by names at Wells Fargo, UBS, and Barclays – the U.S. economy could look very different by January 20. November 14, 2024 | Stansberry Research (Ad)Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNovember 4, 2024 | globenewswire.comSutro Biopharma initiates REFRaME-P1 trial of luvelta in AMLNovember 2, 2024 | markets.businessinsider.comSutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNovember 1, 2024 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comSutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years agoOctober 21, 2024 | finance.yahoo.comSee More Headlines STRO Stock Analysis - Frequently Asked Questions How have STRO shares performed this year? Sutro Biopharma's stock was trading at $4.29 on January 1st, 2024. Since then, STRO stock has decreased by 7.7% and is now trading at $3.96. View the best growth stocks for 2024 here. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) issued its earnings results on Tuesday, August, 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.20. The firm earned $25.71 million during the quarter, compared to the consensus estimate of $26.28 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 102.06% and a negative net margin of 73.48%. When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's top institutional shareholders include Baillie Gifford & Co. (1.85%), Bank of Montreal Can (0.99%), Connor Clark & Lunn Investment Management Ltd. (0.53%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Nicki Vasquez, William J Newell and Brunilda Shtylla. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD). Company Calendar Last Earnings8/13/2024Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$12.14 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+206.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,790,000.00 Net Margins-73.48% Pretax Margin-63.06% Return on Equity-102.06% Return on Assets-29.12% Debt Debt-to-Equity RatioN/A Current Ratio3.41 Quick Ratio3.41 Sales & Book Value Annual Sales$153.73 million Price / Sales2.11 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book1.62Miscellaneous Outstanding Shares81,960,000Free Float77,128,000Market Cap$324.56 million OptionableOptionable Beta1.17 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:STRO) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.